GlassScriptPhysician profile
Yu Xin
NPI 1265962088
$2,615.68
in general payments reported to CMS, 2019-2025
15 companies · $23.47 in 2025
The $23.47 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,521 · 2022: $512 · 2023: $389 · 2024: $170 · 2025: $23.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $718.63 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $619.20 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $291.53 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $268.01 | 2021-2023 | Repatha, Otezla, Prolia |
| Dexcom, INC. | $170.42 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $127.54 | 2021-2023 | |
| Amarin Pharma, INC. | $114.01 | 2021-2022 | |
| Lilly USA, LLC | $79.09 | 2021-2023 | Mounjaro |
| Gilead Sciences, INC. | $56.38 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $53.21 | 2021-2023 | Belsomra, Steglatro |
| Upsher-Smith Laboratories LLC | $33.85 | 2021-2022 | |
| Pfizer INC. | $31.43 | 2021 | |
| Inspire Medical Systems, INC. | $23.47 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $15.90 | 2022 | |
| Eisai INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Xin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.